The objective of this study was to evaluate the pharmacokinetic response to intravenous (IV)
enoxaparin given 8–12 hr after subcutaneous (SC) dosing in patients undergoing …

Plasma anti‐Xa activity after Enoxaparin administration in patients with acute coronary
syndrome (ACS) undergoing coronary angiography and percutaneous coronary intervention …

This study assessed the pharmacokinetics, safety and efficacy of intravenous enoxaparin in
patients undergoing percutaneous coronary intervention (PCI). Sixty consecutive patients …

Background: Many cardiologists continue to be reluctant to utilize low-molecular-weight
heparin in the treatment of patients with non-ST-segment-elevation acute coronary …

Objectives: This study was designed to examine a unique and low dose of intravenous
enoxaparin in elective percutaneous coronary intervention (PCI) that would be applicable to …

Aim Recent studies have suggested that intravenous (iv) enoxaparin could be used as
antithrombotic therapy in patients ongoing percutaneous coronary intervention (PCI) …

Objectives: The aim of this study was to compare efficacy and safety outcomes among
patients receiving enoxaparin or unfractionated heparin (UFH) while undergoing …

Background Despite its limitations, unfractionated heparin has been the standard
anticoagulant used during percutaneous coronary intervention (PCI). Several small studies …

This pilot study was designed to determine whether the low molecular weight heparin,
enoxaparin, could be used for elective percutaneous coronary intervention (PCI) to provide …

Background: Enoxaparin is increasingly used for the anticoagulation of patients undergoing
percutaneous coronary intervention (PCI). Several reports have suggested the utility of using …